Industry Dialogue on PRIP Strengthens Pharma Ecosystem

17 Mar 2025 CW Team

The Department of Pharmaceuticals, Government of India, convened an Industry Dialogue in Mumbai to discuss the Promotion of Research and Innovation in the Pharma-MedTech Sector (PRIP) Scheme. The event brought together industry leaders, research institutions, and pharmaceutical associations, including representatives from the Indian Council for Medical Research (ICMR), the Council of Scientific and Industrial Research (CSIR), and the National Institute of Pharmaceutical Education and Research (NIPERs). Discussions focused on strengthening industry-academia linkages, fostering collaboration, and leveraging government initiatives to accelerate R&D and commercialise innovative solutions in the pharmaceutical and medical technology sectors.

Government Initiatives to Boost Innovation In addition to the PRIP Scheme, the dialogue highlighted key government initiatives aimed at promoting research and innovation in the sector:

ICMR’s PATENT MITRA, MEDTECH MITRA, and INTENT programs – Supporting patent filing, guiding the innovation journey, and facilitating clinical trials. CSIR’s Innovation Complex in Mumbai – Bridging the gap between research institutions and industry through translational research. Industry Leaders Call for Stronger Policy and Investment Support Prominent industry figures voiced their insights on the challenges and opportunities in Pharma-MedTech R&D:

Dr Sharvil Patel, Vice President, Indian Pharmaceutical Association (IPA) – Stressed the importance of industry-driven innovation, regulatory support, and increased investments in emerging pharmaceutical technologies. Mr Anil Matai, Director General, Organisation of Pharmaceutical Producers of India (OPPI) – Highlighted the need for a conducive policy environment to encourage greater industry participation in R&D. Mr Bharat Shah, National President, Indian Drug Manufacturers' Association (IDMA) – Addressed the challenges MSMEs face in adopting research-led growth strategies and welcomed the PRIP scheme’s role in catalysing innovation. Mr Veeraal Gandhi, Vice President, Association of Diagnostics Manufacturers India (ADMI) – Spoke on India’s potential to lead in diagnostic technologies, particularly in point-of-care innovations, to enhance advanced healthcare solutions. Government’s Vision for Future-Ready Healthcare Solutions Shri Amit Agrawal, Secretary, Department of Pharmaceuticals, underscored the importance of futuristic products and affordable healthcare solutions as key drivers of India’s global leadership in pharmaceuticals and MedTech. He emphasised that:

Data-driven markets will play a transformative role in shaping Pharma-MedTech R&D. India, with its highly diverse gene pool and one-sixth of the world’s population, has a unique advantage in developing personalised and precision medicines. The PRIP Scheme aims to support innovative, cost-effective, and affordable healthcare solutions that will strengthen domestic and global healthcare ecosystems. Breakout Sessions and Stakeholder Engagement The event featured breakout sessions, where industry representatives and stakeholders provided insights on emerging R&D trends, regulatory pathways, and funding opportunities. Discussions covered:

Enhancing industry-academia collaboration to drive research and innovation. Streamlining regulatory pathways to facilitate faster commercialisation of new technologies. Scaling up research initiatives to fuel sectoral growth. Stakeholders were encouraged to submit their feedback and project details via the Expression of Interest (EoI) on the Department of Pharmaceuticals website, open until April 7, 2025. This process aims to refine the PRIP Scheme’s implementation to better align with industry needs.

The Industry Dialogue in Mumbai concluded on a highly optimistic note, with participants reaffirming their commitment to fostering an innovation-driven ecosystem in the Pharma-MedTech sector. The event reinforced government-industry collaboration, paving the way for transformative advancements in healthcare, pharmaceuticals, and medical technology.

Infrastructure Urban

04 May 2026

Jyoti Structures FY26 profit rises 56.5%

Jyoti Structures (JSL) recently reported strong financial results for the quarter and year ended 31 March 2026, driven by disciplined execution, cost management and steady progress across its order book.For Q4 FY2025-26, total income rose 44.2 per cent to Rs 2.41 billion from Rs 1.67 billion in Q4 FY2024-25. EBITDA increased 58.6 per cent to Rs 237 million, while EBITDA margin improved by 89 basis points to 9.84 per cent. Profit before tax grew 53.3 per cent to Rs 188.5 million, and net profit rose 51.9 per cent to Rs 181.4 million.For FY2025-26, total income grew 53.1 per cent to Rs 7.72 bill..

Cat BEPU to Power Doppstadt Separator at IFAT 2026

Caterpillar’s Cat Battery Electric Power Unit (BEPU) has been selected by Doppstadt to power its SWS 6 Spiral Shaft Separator, which will be showcased for the first time at IFAT 2026 in Munich, Germany, from 4–7 May.The compact plug-and-play BEPU is designed to replace a diesel engine within the same space, using the same mounting locations and relative machine position. It integrates the battery, motor, inverter, onboard charging, cooling and controls, enabling OEMs to electrify existing chassis platforms without extensive redesign.Caterpillar and Cat dealer Zeppelin Power Systems have be..

VECV sales rise 6.9% in April 2026

VE Commercial Vehicles, a joint venture between Volvo Group and Eicher Motors, recorded sales of 7,318 units in April 2026, compared to 6,846 units in April 2025, registering 6.9 per cent growth. The total included 7,159 units under the Eicher brand and 159 units under the Volvo brand.Eicher branded trucks and buses reported sales of 7,159 units during the month, up 6.6 per cent from 6,717 units in April 2025. In the domestic commercial vehicle market, Eicher sales rose 8.6 per cent to 6,797 units from 6,257 units a year earlier.Exports declined 21.3 per cent, with VECV recording 362 units in ..